Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nearly four months after issuing a voluntary recall of all lots of unexpired sterile drug products, Cantrell Drug Company has filed for bankruptcy.
The PE firm made the investment just three years ago.
A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.
Tonghua Golden-Horse Pharma and Golden Meditech Holdings -- will submit bids in the second round of an auction to acquire I-MED Radiology.
Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment.
The acquisition is expected to close by the end of 2017.
Neurocrine’s third-quarter financial results didn’t just impress, they blew everybody away.
Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.